Stay updated on REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial page.

Latest updates to the REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision label updated from v3.2.0 to v3.3.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedThe funding-status warning about government delays has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check34 days agoChange DetectedResults for NCT03515629 have been posted, including updates to primary and secondary outcomes and the overall study status. The primary endpoint PFS is noted as not assessed due to insufficient data, with other outcomes outlined.SummaryDifference0.4%

- Check62 days agoChange DetectedMajor update: operating-status notice and new version v3.2.0; old v3.1.0 reference removed.SummaryDifference4%

- Check69 days agoChange DetectedUpgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.SummaryDifference0.1%

- Check84 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, and the 'Back to Top' element was removed as a minor UI cleanup.SummaryDifference0.2%

Stay in the know with updates to REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial page.